H
HDT Bio
A biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases
About HDT Bio
HDT Bio is a clinical-stage private company based in Seattle, specializing in the development of advanced RNA vaccine products aimed at treating and preventing infectious diseases and cancers. The company leverages its proprietary AMPLIFY vaccine platform, which combines self-amplifying RNA technology to offer increased potency, superior safety, and durability compared to traditional mRNA vaccines. HDT Bio operates in the biotechnology sector, focusing on rigorous clinical research and robust data generation to validate its innovative approaches. The company primarily serves healthcare providers, researchers, and pharmaceutical companies looking for cutting-edge vaccine solutions. HDT Bio's business model revolves around developing and licensing its RNA vaccine technology, conducting focused clinical trials, and seeking partnerships and collaborations to expand its impact. Revenue is generated through licensing agreements, research grants, and potential future sales of approved vaccine products.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Seattle, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Zoic Capital
National Institutes of Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HDT Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HDT Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.